Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL68916 | 0.98 | HTR2C (0.55) | HTR2CDDB1CRBNSLC6A2SLC6A4 | |
| SCHEMBL22324786 | 0.77 | MEN1 (0.42) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| Hydrochloric Acid SCHEMBL10667309 | 0.76 | MEN1 (0.41) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| Hydrochloric Acid SCHEMBL70804 | 0.75 | HTR2C (0.51) | HTR2CDDB1CRBNSLC6A2SLC6A4 | |
| SCHEMBL83025 | 0.74 | MEN1 (0.42) | HTR2CSLC6A2SLC6A4MEN1CYP1A2 | |
| SCHEMBL83809 | 0.74 | CYP1A2 (0.50) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL15888653 | 0.74 | HTR2C (0.50) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| Hydrochloric Acid SCHEMBL68997 | 0.72 | MEN1 (0.41) | HTR2CSLC6A2SLC6A4MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL72071 | 0.72 | CYP1A2 (0.49) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL8863558 | 0.71 | NOTUM (0.45) | HTR2CDDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | HTR2C 3384/4885DDB1 2642/4885CRBN 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.